Literature DB >> 11035738

Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

H W Murray1.   

Abstract

In experimental visceral leishmaniasis, acquired resistance to intracellular Leishmania donovani is Th1 cell cytokine dependent and largely mediated by gamma interferon (IFN-gamma); the same response also permits conventional antimony (Sb) chemotherapy to express its leishmanicidal effect. Since the influxing blood monocyte (which utilizes endothelial cell ICAM-1 for adhesion and tissue entry) is a primary effector target cell for this cytokine mechanism, we tested the monocyte's role in host responsiveness to chemotherapy in mice with ICAM-1 gene disruptions. Mutant animals failed to develop any early granulomatous tissue response in the liver, initially supported high-level visceral parasite replication, and showed no killing after Sb treatment; the leishmanicidal response to a directly acting, alternative chemotherapeutic probe, amphotericin B, was intact. However, mutant mice proceeded to express a compensatory, ICAM-1-independent response leading to mononuclear cell influx and granuloma assembly, control over visceral infection, and the capacity to respond to Sb. Together, these results point to the recruitment of emigrant monocytes and mononuclear cell granuloma formation, mediated by ICAM-1-dependent and -independent pathways, as critical determinants of host responsiveness to conventional antileishmanial chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035738      PMCID: PMC97712          DOI: 10.1128/IAI.68.11.6294-6299.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

Review 1.  Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.

Authors:  H W Murray
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

2.  Host defenses against disseminated candidiasis are impaired in intercellular adhesion molecule 1-deficient mice.

Authors:  S L Davis; E P Hawkins; E O Mason; C W Smith; S L Kaplan
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 3.  Lymphocyte interactions with endothelial cells.

Authors:  Y Shimizu; W Newman; Y Tanaka; S Shaw
Journal:  Immunol Today       Date:  1992-03

4.  T-cell-mediated immunity to lymphocytic choriomeningitis virus in beta2-integrin (CD18)- and ICAM-1 (CD54)-deficient mice.

Authors:  J P Christensen; O Marker; A R Thomsen
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner.

Authors:  S E Cotterell; C R Engwerda; P M Kaye
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

6.  Intercellular adhesion molecule 1 is the major adhesion molecule expressed during schistosome granuloma formation.

Authors:  D M Ritter; J H McKerrow
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

7.  Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains.

Authors:  T I Roach; A F Kiderlen; J M Blackwell
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  T cell interaction with ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells.

Authors:  Y Reiss; G Hoch; U Deutsch; B Engelhardt
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

9.  Role and effect of TNF-alpha in experimental visceral leishmaniasis.

Authors:  M C Tumang; C Keogh; L L Moldawer; D C Helfgott; R Teitelbaum; J Hariprashad; H W Murray
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

10.  Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15.

Authors:  D Sancho; M Yáñez-Mó; R Tejedor; F Sánchez-Madrid
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

View more
  23 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

3.  Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.

Authors:  Henry W Murray; Andrew D Luster; Hua Zheng; Xiaojing Ma
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

4.  Liposomal resiquimod for the treatment of Leishmania donovani infection.

Authors:  Kevin J Peine; Gaurav Gupta; Deanna J Brackman; Tracey L Papenfuss; Kristy M Ainslie; Abhay R Satoskar; Eric M Bachelder
Journal:  J Antimicrob Chemother       Date:  2013-08-16       Impact factor: 5.790

5.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

6.  Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis.

Authors:  Neetu Singh; Rajiv Kumar; Shashi Bhushan Chauhan; Christian Engwerda; Shyam Sundar
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

7.  Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.

Authors:  Anthony D Duong; Sadhana Sharma; Kevin J Peine; Gaurav Gupta; Abhay R Satoskar; Eric M Bachelder; Barbra E Wyslouzil; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

8.  A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Gaurav Gupta; Kevin J Peine; Dalia Abdelhamid; Heidi Snider; Andrew B Shelton; Latha Rao; Sainath R Kotha; Andrew C Huntsman; Sanjay Varikuti; Steve Oghumu; C Benjamin Naman; Li Pan; Narasimham L Parinandi; Tracy L Papenfuss; A Douglas Kinghorn; Eric M Bachelder; Kristy M Ainslie; James R Fuchs; Abhay R Satoskar
Journal:  ACS Infect Dis       Date:  2015-09-21       Impact factor: 5.084

9.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Authors:  Henry W Murray
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.